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ABSTRACT
Infertility concerns 15% of the couples. Management of female infertility requires a complete history of
the patient followed by a physical, gynecological and endocrine examination. Infertility etiology will be
investigated thanks to different tests including ovarian function and reserve assessment, search for uter-
ine abnormalities and evaluation of tubal permeability. Polycystic ovarian syndrome (PCOS) is a predomin-
ant cause of infertility and a common gyne-endocrine disorder affecting 7 to 15% of women in
reproductive age. Behavioral, medical and surgical treatments have been evaluated in order to improve
the fertility of women with PCOS. Lifestyle modifications (stop smoking, physical exercise and weight loss
when necessary) are of the utmost importance. Clomiphene citrate remains the first line of medical treat-
ment of infertility in women with PCOS in absence of other male or female causes of infertility. Use of
metformin solely for infertility is not recommended in absence of metabolic anomaly and new treatment
as myoinositol is emerging. Surgical techniques aiming to enhance ovulation and pregnancy rate are an
option when medical treatment failed. Ovarian drilling by laparoscopy or by transvaginal hydrolaparo-
scopy is taking a larger place in the treatment of infertility. In vitro maturation and fertilization remain
the third-line of treatment in PCOS.
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Polycystic ovary syndrome (PCOS) is an endocrine and repro-
ductive disorder affecting 7 to 15% of women of reproductive
age. It was first described by Stein and Leventhal in 1935. PCOS
etiology is complex, including genetic, environmental and life-
style factors and remains controversial. PCOS is defined by the
presence of at least two of the Rotterdam criteria: oligo-anovula-
tion, clinical or biological hyperandrogenism, and micropolycys-
tic syndrome (ovarian volume > 10ml and/or more than 12
follicles by the ovary) [1–3].
Patients suffering from PCOS will consult for different
degrees of hyperandrogenism (hirsutism, seborrhea, acne), dys-
function of the menstrual cycles, overweight, infertility
A delayed diagnostic has been well documented in the litera-
ture explained in part by the lateness of the referral to a special-
ist, often for infertility [4]. PCOS is the first cause of anovulatory
infertility nowadays and infertility is found in 70 to 80% of
affected women [5].
The purpose of this article is to overview different available
options to improve fertility in PCOS. A specific emphasis will be
given to ovarian drilling, a less commonly used surgical tech-
nique that has some added values.
Evaluation of infertility in PCOS patients
Evaluation of infertility (or subfertility) is recommended after 12
months without pregnancy in couples having regular sexual
intercourse (2 or 3 times/week) [1].
PCOS is the first cause of female infertility but the definite
diagnosis should be given after exclusion of other etiologies of
infertility such as other endocrine disorders (thyroid dysfunction,
hyperprolactinemia, congenital adrenal hyperplasia, Cushing syn-
drome, premature ovarian insufficiency, … ), anatomical dys-
functions (endometriosis, pelvic inflammatory diseases, … ) or
iatrogenic causes (surgery, chemotherapy, radiations, … ).
The patient’s personal medical and surgical as well as familial
history, followed by a complete physical and gynecological exam-
ination is mandatory when exploring infertility. A thorough table
with the infertility factors to search can be found in the supple-
mental data.
Additional diagnostic tests including blood samples, ultrason-
ography and hysteroscopy among others are recommended.
Anti-m€ullerian hormone (AMH) is a useful test in the evalu-
ation of infertility. It is produced by granulosa cells of early fol-
licles and helps to evaluate the ovarian reserve. Because its
production is gonadotrophin-independent, AMH levels remain
consistent during the menstrual cycle [1]. Women with PCOS
present AMH levels 2 to 3 folds higher than non-PCOS women
because of an increased number of preantral and small antral fol-
licles. The increased AMH level seems correlated with the sever-
ity of PCOS [6].
Transvaginal ultrasonography (TVUS) will evaluate the antral
follicle count, endometrium thickness and diagnose uterine
anomaly (polyps, myomas and congenital malformation).
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Treatment
Non-pharmacologic measures remain the first line and the most
effective in the treatment of infertility. We already know the
positive effects of clomiphene citrate letrozole and gonadotropins
in the treatment of infertility in PCOS. Myo-inositol and ovarian
drilling are new lines of therapeutic and will be discussed in this
review. This review includes articles until March 2021.
Non-pharmacological measures
Lifestyle changes are the first line of treatment for women with
PCOS. In all cases, smoking should be ceased and physical exer-
cise encouraged. Weight loss is recommended in overweight and
obese women [7].
Several studies [2,8] have shown that a 5 to 10% weight loss
in overweight and obese women may be sufficient to restore
regular menstruation and ovulation [9]. This weight loss also
enhances the effect of the ovulation-inducing agents. Altogether,
weight loss in obese women with PCOS improves pregnancy rate
in addition to the known metabolic benefits [10].
Bariatric surgery can be considered when BMI is above 35 kg/
m2 and lifestyle changes conducted for more than 1 year have
failed [11]. A meta-analysis showed that obese women suffering
from PCOS with bariatric surgery presented a significant
decrease in testosterone levels associated with a resolution of hir-
sutism in 53% and of menstrual irregularities in 96% of the sub-
jects [12]. However, there is currently no strong evidence
suggesting that bariatric surgery improves the pregnancy rate in
women with PCOS. Moreover, surgical complications, intestinal
incarceration in Petersen space and lack of vitamins should not
be neglected [13,14].
Metformin
Due to the key role of insulin resistance in PCOS, off-label use
of metformin (an insulin sensitizer) has been considered as a
first-line treatment for PCOS for many years. Several studies
have suggested that metformin (alone or in association with
Clomiphene) increased ovulatory cycles in women with PCOS
[15]. However, pooled analyses also showed that it does not
increase the live birth rate [16,17]. Therefore, the current guide-
lines do not recommend the use of metformin for ovulation
induction and limit the use of this drug to insulin resistance in
PCOS and type 2 diabetes [3].
Treatment already confirmed
First line of treatment
Clomiphene citrate. Clomiphene citrate (CC) remains the first-
line ovulation induction drug in women with PCOS suffering
from infertility [15]. CC is an anti-estrogen therapy that blocks
estrogen receptors in the hypothalamus and, with the negative
feedback mechanism, leads to a stimulation of the follicular
development [5,18,19]. Administration of CC has to be moni-
tored (by ultrasound and endocrine blood sample) to appreciate
the day of the ovulation and to prevent multiple pregnancies
(rate of 11% risk) [20–23]. As monitoring, ultrasound evaluation
is done on days 11 to 14, and measures of the follicular growth
and endometrial thickness are also performed [20–23].
Letrozole. Letrozole is a member of the aromatase inhibitors fam-
ily. Aromatase inhibitors result in lower E2 levels. This strongly
reduces the risk of multiple follicle development. This is one of
the main advantages of letrozole among CC. The other advan-
tage is that letrozole does not affect endometrial estrogen recep-
tors, and therefore does not exert any deleterious effect on
endometrial thickness and cervical mucus [24,25]. Mejia and al
suggest a higher ovulation rate with letrozole but there is no evi-
dence of a higher pregnancy rate with this therapy [26]
However, recommendations remain that letrozole is a second-
line of treatment for women who have CC resistance or failure
without another infertility factor [27].
Second line therapeutic options: gonadotropin therapy
A second-line therapeutic option is gonadotropin therapy associ-
ated with timed intercourse. For women with PCOS, all recom-
mendations now agree to use a low-dose step-up regimen to
prevent ovarian hyperstimulation syndrome (OHSS) and multiple
pregnancies. The high number of antral follicles in women with
PCOS predispose them to develop OHSS [28,29].
Third line of treatment: in vitro fertilization and
in vitro maturation
When the second-line treatment options have failed, more com-
plex therapies should be proposed, mainly in vitro fertilization
(IVF) and, more recently, in vitro maturation (IVM).
IVF protocols use the combined action of gonadotropins with
gonadotropin-releasing hormone agonist and antagonist.
Complications of this technique are multiple pregnancies and
OHSS. After ovulation, multiple luteinized cysts are present
within the ovaries leading to larger ovaries with higher vascular
permeability resulting in a third space because of the shift of the
fluids. Estrogens, progesterone and local cytokines are released as
a vascular endothelial growth factor which encourages vascular
hyperpermeability. The creation of a third space can lead to
hypovolemia, renal insufficiency, and death. Women with PCOS
are predisposed to develop OHSS because of the high number of
antral follicles [30].
The IVF-associated high risk of OHSS and multiple pregnan-
cies in women with PCOS may be avoided with the in vitro mat-
uration (IVM) procedure. IVM involves a short duration of
gonadotrophin stimulation without a trigger injection [31].
Oocytes are retrieved from smaller follicles than what is done in
conventional IVF. Oocyte meiosis and maturation to metaphase
II occurs in vitro. Particularly appealing for PCOS women, this
technique is also an opportunity to minimize exposure to high




Inositol is one of the therapeutic alternatives which has recently
been investigated [23]. It acts as the first line of treatment. There
are nine different stereoisomers of inositol. Myoinositol is widely
found in nature in plants and animal tissues. D-chiro-inositol is
the second common isomer. Inositol can be produced in human
cells from glucose and is directly involved in insulin cellular sig-
naling [32]. It acts as an intracellular second messenger to regu-
late hormones like TSH, FSH and insulin. Inositol plays different
roles with these stereoisomers, one enhancing cell glucose
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transportation through the stimulation of the glucose-transporter
4 (GLUT4) translocation to the cell membrane, a second one
downregulating the release of free fatty acids from adipose tissue.
D-chiro-inositol upregulates the pyruvate dehydrogenase enzyme
leading to the production of adenosine triphosphate (ATP),
glycogen synthesis and in the ovaries, regulating the insulin-
induced androgen synthesis. Myoinositol and D-chiro-inositol
promote the enzyme-inducing the conversion from glucose
to glycogen.
Myoinositol modulates the activation of glucose utilization
and glucose transporters and regulates glucose uptake and FSH
signaling in the ovaries.
Administration of D-chiro-inositol has been proved to reduce
insulin resistance. Inositol improves the metabolic profile of
PCOS patients. Some studies report that the dose needed is 1 g
D-chiro-inositol þ 400mcg folic acid per day to reduce meta-
bolic syndrome and to increase the glycemia/insulin ratio [33].
Regidor et al. studied the effect of combined treatment with
2 2000mg myo-inositol and 2 200mcg folic acid per day for
2 and 3 months. They suggested that a myo-inositol therapy in
women with PCOS induced a better fertilization rate and better
embryo quality. Therefore, the use of myo-inositol is recom-
mended as an improvement in IVF protocols for patients with
PCOS with a dose of 4000mg per day [34].
Studies also demonstrated a role of inositol in metabolic dis-
orders and human reproduction as in ovulation [35]. Pundir
et al. [36], in their review, found that inositol supplementation
appeared to increase the rates of ovulation and the frequency of
menstrual cycles. Nevertheless, no studies found a better live
birth rate.
Ovarian drilling
An alternative treatment is laparoscopic or transvaginal ovarian
drilling, also called ovarian diathermy or electrocoagulation. It
acts as a second line of treatment. Indeed, this technique can be
proposed after 4 to 6 cycles of CC and before treatment with
gonadotrophins [5]. Ovarian drilling is a technique consisting of
puncturing the ovaries. The aim of the technique is to penetrate
the ovarian capsule with an electrosurgical probe at a number of
points (3 to 6 punctures). Each point measuring 4mm in diam-
eter and 5–7mm in-depth and the duration of the penetration is
5 s. This technique replaces cuneiform resection of the ovaries.
Cuneiform resection leads to adherences and surgical complica-
tions and was performed before the beginning of the ovarian
drilling technique. [37] (Figure 1).
The first laparoscopic ovarian drilling was performed in 1984
and the first transvaginal laparoscopy in 2001. Both techniques
can be used [38,39].
Technique. Laparoscopic ovarian cautery is performed with a
traditional endoscope and two additional trocars. The whole
length of the unipolar needle electrode is inserted into the ovary
with a setting of 40W for 4–5 s. The laparoscopic technique is
the recommended procedure for ovarian drilling.
Transvaginal hydrolaparoscopy is performed with saline solu-
tion in the peritoneal cavity. The endoscope has an angle of 30
degrees and permits examination of the entire pelvic cavity.
Salpingoscopy with fallopian tube and fimbriae inspection can
also be performed by transvaginal laparoscopy (THL) [40].
Bilateral ovarian drilling was performed, with about 10 perfora-
tions in each ovary and a depth of insertion of 10mm. This
technique can be realized with spinal anesthesia [41].
The risks associated with ovarian drilling are those linked to
any surgical procedure and the risk of creating adhesion. The
choice of the technique (laparoscopy versus THL) may influence
safety. Giampaolino et al. compared the benefits of laparoscopy
versus THL [40]. Results showed that THL is faster, reduces
adhesions, and is better tolerated by the patients (less post-opera-
tive pain). The mechanisms of these benefits could be the instal-
lation of saline solution, the shorter duration, the use of bipolar
diathermy and the reduction of bleeding due to lower manipula-
tion of the ovaries than during a laparoscopy.
THL is also an easier approach for women with obesity
[40,42]. Finally, Giampaolino et al. also suggest that the learning
curve with THL is shorter than with laparoscopy.
Nevertheless, the risk of this technique is a perforation of the
rectum, (0.5% risk) [43]. Should this happen, it is usually man-
aged by conservative treatment and antibiotics. A second-look
laparoscopy will be performed to confirm the periton-
eal integrity.
Mechanism of action. The mechanism of action of ovarian drilling
is still poorly understood. It seems that ovarian drilling impairs
local androgen synthesis and reduces intraovarian androgen level
which decreases the inhibitory effect on follicular maturation.
Lower levels of androgens diminish the peripheral conversion of
androgen to estrogen and decrease the positive feedback on LH
secretion. Recruitment of new follicles is permitted spontaneously
or with exogenous FSH stimulation [44] (Figure 2).
This technique improves hirsutism and acne, irregular cycles,
the occurrence of ovulation and pregnancy [41,45].
Ovarian drilling does not require the monitoring of ultra-
sound and avoids the risk of multiple pregnancies or OHSS [41].
In 2020, a Cochrane review showed moderate-quality evidence
that laparoscopic ovarian drilling probably reduces the number
of multiple pregnancies and may result in less OHSS [46].
The efficacy of ovarian drilling is variable in the literature.
Ovulation and pregnancy rates of 30 to 90% and 13 to 80%,
respectively, have been reported [47]. Factors increasing the effi-
cacy of the technique are high LH concentration (>10UI/l),
short infertility duration (<3 years), age (<35 years) and low
antral follicle count (<50) [48]. High BMI (>35kg/m2), insulin
resistance and high testosterone concentration are negative fac-
tors for the effectiveness of this treatment [41].
The choice of the technique may also influence the results. In
the first 6 months following THL, Giampaolino et al.
Figure 1. Laparoscopic surgery of ovarian drilling.
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demonstrated in 2018 that ovulation occurred in 82.9% of the
patients associated with a pregnancy rate of 70% [41].
Besides its efficacy in terms of pregnancy rate, the other big
advantage of ovarian drilling is the long-term maintenance of its
benefits. Indeed, studies have shown that improvement/reso-
lution of the symptoms will persist up to 20 years after the pro-
cedure in more than 60% of the patients. This long-term efficacy
is not achieved with the other treatment options of PCOS
(excepted lifestyle modifications when they are maintained
through the years) [30]. Debras et al. showed in 2020 in a retro-
spective study that ovarian drilling permits spontaneous preg-
nancy and has a long-term effect. The predictive factors for this
effectiveness were a normal body mass index (BMI), an infertility
period of less than three years, an AFC of less than 50, and an
age of less than 35 [44].
Conclusion
PCOS is a frequent syndrome and the most frequent cause of infer-
tility. PCOS is defined as a syndrome with at least two of three of
the Rotterdam criteria. A complete evaluation of the infertility is
needed to exclude other causes of infertility. PCOS treatment is still
controversial but three lines of therapies were discussed. The first
line of treatment remains lifestyle modifications and bariatric sur-
gery-associated or not with metformin and myoinositol.
Clomiphene citrate and letrozole are considered also as the first line
of treatment. Gonadotrophin therapy and ovarian drilling are the
second line of treatment. Nevertheless, the place of transvaginal
hydrolaparoscopic ovarian drilling is still not well clarified. Further
studies are necessary to encourage this technique. If the patient is
still resistant to those therapies, a third-line of treatment is pro-
posed as in vitro fertilization and in vitro maturation.
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Gynecological history including duration of infertility, menstrual
cycle length and menstrual bleeding characteristics has to be noted.
Physical examination includes the body mass index, blood pres-
sure, signs of hyperandrogenism, acanthosis, exophthalmos, develop-
ments of second sexual characters, … hyperandrogenism is often
characterized by acne (on more than 2 sites on the body) and hirsut-
ism. Hirsutism is diagnosed by an excess of hair on androgenic
regions well defined by Ferriman and Gallway score. Androgenic
alopecia and acanthosis can also be highlighted.
Tenderness of posterior cul-de-sac, uterosacral ligaments, tumors,
uterine abnormalities have also to be noticed during the gyneco-
logical examination.
The most important items to cover during anamnesis and exam-
ination are listed in Table A1.




Abdominal pain, dyspareunia, dysmenorrhea
Medications
Surgical history






Review of the past pregnancies and deliveries, if any
Sexual intercourse frequency
Lifestyle history
Diet, exercice and smoking habits
Family history
Family history of infertility, birth defect, known or suspected genetic mutation
Physical Examination
Body mass index
Development of secondary sexual characteristics
Signs of hyperandrogenism (seborrhea, acne, hirsutism)
Galactorrhea
Thyroid goiter, dry skin, exophtalmos
Acanthosis
Gynecological examination
Tenderness or masses in the adnexae, posterior cul-de-sac, uterosacral ligaments, or rectovaginal septum
suggesting pelvic inflammatory disease or endometriosis
Vaginal, cervical or uterine abnormalities suggesting infection, malformation or tumors.
Medical doses.
Clomiphene citrate.
Usually, an initial dose of 50mg/day CC is given for 5 consecutive days, staring on menstrual cycle days 2 to
5. If there is no response after 2 cycles, the dose may be increased. It is recommended not to exceed 150mg/
day. On the other hand, dose can also be decreased to 25mg/day if there is an over-response. When ovulatory
cycles are achieved, the treatment should be maintained at the same dose for a maximum of 6 cycles [29].
After three to 6 unsuccessful cycles, CC-resistant patients can be identified and an alternative treatment is pro-
posed [30].
Approximatively 75% of the pregnancies that occur with CC are obtained in the first three cycles of treatment.
Letrozole.
Starting dose recommended is 2.5mg/day of letrozole administrated between menstrual cycle day 3 and day
7. It can be raised up to a maximum of 7.5mg/day. Transvaginal ultrasound is performed on day 3 of the
menstrual cycle before the initiation of the treatment and follicular development is monitored on day 10 by
ultrasound. If there is at least one mature follicle, 10 000 UI of human chorionic gonadotropin are given to
trigger ovulation [31] and sometimes ovulation occurs by itself. Pelvic ultrasound allows to define which
patient will have hCG or not.
Gonadotrophins.
The low-dose step-up regimen starts with a dose of 50–75 UI/day. In absence of ovarian response (based on
ultrasound images and circulating E2 level) for 14 days, the dose of FSH is increased step wisely by 25-37.5 UI/
day every 7 days [42].
Step-down regimens can also be used with a dose of 150 UI/day for 3 to 4 days before decreasing the dose to
50-75 UI/day. The higher dose enhances follicular recruitment while lower dose maintains follicular
development.
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